CLRB - Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia | Benzinga
William Yoon Appointed Vice President, Medical Affairs
Aaditya Nanduri Appointed Vice President, Business Strategy and Analytics
FLORHAM PARK, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, is pleased to announce the appointment of William Yoon, PharmD, MBA/HCM as vice president, medical affairs and Aaditya Nanduri, MS, as vice president, business strategy and analytics ahead of the expected readout of top-line pivotal data for iopofosine I 131 in Waldenstrom's macroglobulinemia (WM) in Q4 2023.
"As we prepare for the release of pivotal data, potential NDA filing and planned US product launch of iopofosine I 131 in 2024, we are dedicated to building a commercialization team with strong experience and a track record of success in the hematology and oncology space," said James Caruso, president and CEO of Cellectar. "We welcome William Yoon and Aaditya Nanduri to our team where their expertise will play an important role in the preparation of our WM launch planning and subsequent market execution."
Dr. Yoon possesses over three decades of experience in the drug distribution and pharmaceutical industry. His expertise includes more than twenty years in Medical Affairs, with a strong emphasis on hematology and oncology. Prior to joining Cellectar Biosciences, he held the position of Head of Clinical and Value Evidence at Immunogen Inc. Dr. Yoon's extensive career also encompasses nearly twenty years with Novartis Corporation, where he contributed to various business units, including oncology. During his tenure at Novartis, he held several leadership roles, including Head of Population Health Account Management, Head of US External Engagement and Medical Advocacy, and Executive Director and Head of US Medical Managed Markets and Strategic Alliances, among others. Dr. Yoon played a pivotal role in advancing the field of biosimilars, leading efforts to launch the first biosimilar in the US and facilitating patient access to these life-saving medicines. He earned his bachelor's degree in pharmacy from Purdue University and a Doctor of Pharmacy degree from Shenandoah University. Additionally, he holds a Master of Business Administration in Healthcare Management from the University of Phoenix.
Mr. Nanduri ...